Toward second generation hepatitis C virus NS3 serine protease inhibitors: Discovery of novel P4 modified analogues with improved potency and pharmacokinetic profile

Journal of Medicinal Chemistry

Volumn 52, Issue 9, 2009, Pages 2806-2817

  Arasappan, Ashok ^a   Padilla, Angela I ^a   Jao, Edwin ^a   Bennett, Frank ^a   Bogen, Stephane L ^a   Chen, Kevin X ^a   Pike, Russell E ^a   Sannigrahi, Mousumi ^a   Soares, Joana ^a   Venkatraman, Srikanth ^a   Vibulbhan, Bancha ^a   Saksena, Anil K ^a   Girijavallabhan, Viyyoor ^a   Tong, Xiao ^a   Cheng, Kuo Chi ^a   Njoroge, F George ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[[[1 (2,3 DIHYDRO 1H INDEN 2 YL) 2 [(2 [[[1 [1,2 DIOXO 2 (2 PROPENYLAMINO)ETHYL]BUTYL]AMINO]CARBONYL] 6,6 DIMETHYL 3 AZABICYCLO[3.1.0]HEX 3 YL] 2 OXOETHYL]AMINO]CARBONYL]AMINO] 3,3 DIMETHYLBUTYLETHYLCARBAMATE; 2 [[[[2 [2 [[[1 [1,2 DIOXO 2 (2 PROPENYLAMINO)ETHYL] 4 PENTYNYL]AMINO]CARBONYL] 6,6 DIMETHYL 3 AZABICYCLO[3.1.0]HEX 3 YL] 1 (1 METHYLCYCLOHEXYL) 2 OXOETHYL]AMINO]CARBONYL]AMINO] 3,3 DIMETHYLBUTYL (1 METHYLETHYL)CARBAMATE; 2 [[[[2 [2 [[[1 [1,2 DIOXO 2 (2 PROPENYLAMINO)ETHYL] 4 PENTYNYL]AMINO]CARBONYL] 6,6 DIMETHYL 3 AZABICYCLO[3.1.0]HEX 3 YL] 1 (1 METHYLCYCLOHEXYL) 2 OXOETHYL]AMINO]CARBONYL]AMINO] 3,3 DIMETHYLBUTYL (2 METHYLPROPYL)CARBAMATE; 2 [[[[2 [2 [[[1 [1,2 DIOXO 2 (2 PROPENYLAMINO)ETHYL] 4 PENTYNYL]AMINO]CARBONYL] 6,6 DIMETHYL 3 AZABICYCLO[3.1.0]HEX 3 YL] 1 (1 METHYLCYCLOHEXYL) 2 OXOETHYL]AMINO]CARBONYL]AMINO] 3,3 DIMETHYLBUTYL (CYCLOPROPYLMETHYL)CARBAMATE; 2 [[[[2 [2 [[[1 [1,2 DIOXO 2 (2 PROPENYLAMINO)ETHYL] 4 PENTYNYL]AMINO]CARBONYL] 6,6 DIMETHYL 3 AZABICYCLO[3.1.0]HEX 3 YL] 1 (1 METHYLCYCLOHEXYL) 2 OXOETHYL]AMINO]CARBONYL]AMINO] 3,3 DIMETHYLBUTYLETHYLCARBAMATE; 2 [[[[2 [2 [[[1 [1,2 DIOXO 2 (2 PROPENYLAMINO)ETHYL]BUTYL]AMINO]CARBONYL] 6,6 DIMETHYL 3 AZABICYCLO[3.1.0]HEX 3 YL] 1 (1 METHYLCYCLOHEXYL) 2 OXOETHYL]AMINO]CARBONYL]AMINO] 3,3 DIMETHYLBUTYL (1 METHYLETHYL)CARBAMATE; AMIDE; BOCEPREVIR; CARBAMIC ACID; NONSTRUCTURAL PROTEIN 3; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG SELECTIVITY; HEPATITIS C VIRUS; NONHUMAN; RAT; REPLICON; STRUCTURE ACTIVITY RELATION; TARGET ORGAN;

AMIDES; ANIMALS; DRUG DISCOVERY; HEPACIVIRUS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROTEASE INHIBITORS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL NONSTRUCTURAL PROTEINS;

EID: 65749118566     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801616e     Document Type: Article

References (24)

1. (a) Cohen, J. The scientific challenge of hepatitis C. Science 1999, 285, 26-30.
2. (b) Houghten, M. In Virology; Fields, B. N., Knipe, D. M., Howley, P. M., Eds.; Raven Press: New York, 1996; pp 1035-1058.
3. (c) Cuthbert, J. A. Hepatitis C: progress and problems. Clin. Microbiol. Rev. 1994, 7, 505-532.
4. Consensus Panel. EASL International Consensus Conference on Hepatitis C, Paris, 26-28 February 1999, Consensus Statement. J. Hepatol. 1999, 30, 956
5. Dymock, B. W. Emerging therapies for hepatitis C infection. Emerging Drugs 2001, 6 (1), 13-42. (Pubitemid 32381375)
6. Feld, J. J; Hoofnagle, J. H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature (London) 2005, 436, 967-972. (Pubitemid 41191673)
7. (a) De Francesco, R; Migliaccio, G. Challenges and successes in developing new therapies for hepatitis C. Nature (London) 2005, 436, 953-960. (Pubitemid 41191671)
8. (b) De Francesco, R.; Tomei, L.; Altamura, S.; Summa, V.; Migliaccio, G. Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. Antiviral Res. 2003, 58, 1-16. (Pubitemid 36507217)
9. (c) Steinkuhler, C.; Koch, U.; Narjes, F.; Matassa, V. G. Hepatitis C virus serine protease inhibitors: current progress and future challenges. Curr. Med. Chem. 2001, 8, 919-932. (Pubitemid 32633550)
10. (a) Kolykhalov, A. A.; Mihalik, K.; Feinstone, S. M.; Rice, C. M. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo. J. Virol. 2000, 74, 2046-2051. (Pubitemid 30434065)
11. (b) Bartenschlager, R.; Lohmann, V. Replication of hepatitis C virus. J. Gen. Virol. 2000, 81, 1631-1648. (Pubitemid 30427068)
12. (a) Llinas-Brunet, M.; Bailey, M. D.; Bolger, G.; Brochu, C.; Faucher, A.-M.; Ferland, J. M.; Garneau, M.; Ghiro, E.; Gorys, V.; Grand-Maitre, C.; Halmos, T.; Lapeyre-Paquette, N.; Liard, F.; Poirier, M.; Rheaume, M.; Tsantrizos, Y. S.; Lamarre, D. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061. J. Med. Chem. 2004, 47, 1605-1608. (Pubitemid 38386628)
13. (b) Perni, R. B.; Almquist, S. J.; Byrn, R. A.; Chandorkar, G.; Chaturvedi, P. R.; Courtney, L. F.; Decker, C. J.; Dinehart, K.; Gates, C. A.; Harbeson, S. L.; Heiser, A.; Kalkeri, G.; Kolaczkowski, E.; Lin, K.; Luong, Y.-P.; Rao, B. G.; Taylor, W. P.; Thomson, J. A.; Tung, R. D.; Wei, Y.; Kwong, A. D.; Lin, C. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob. Agents Chemother. 2006, 50, 899-909. (Pubitemid 43327793)
14. (c) Zeuzem, S.; Sarrazin, C.; Rouzier, R.; Tarral, A.; Brion, N.; Forestier, N.; Gupta, S.; Deckman, D.; Fellows, K.; Hussain, M.; Cutler, D.; Zhang, J. In 56th Annual Meeting of AASLD, 2005, San Francisco, CA.
15. Venkatraman, S.; Bogen, S. L.; Arasappan, A.; Bennett, F.; Chen, K.; Jao, E.; Liu, Y.-T.; Lovey, R.; Hendrata, S.; Huang, Y.; Pan, W.; Parekh, T.; Pinto, P.; Popov, V.; Pike, R.; Ruan, S.; Santhanam, B.; Vibulbhan, B.; Wu, W.; Yang, W.; Kong, J.; Liang, X.; Wong, J.; Liu, R.; Butkiewicz, N.; Chase, R.; Hart, A.; Agrawal, S.; Ingravallo, P.; Pichardo, J.; Kong, R.; Baroudy, B.; Malcolm, B.; Guo, Z.; Prongay, A.; Madison, V.; Broske, L.; Cui, X.; Cheng, K.-C.; Hsieh, T. Y.; Brisson, J.-M.; Prelusky, D.; Korfmacher, W.; White, R.; Bogdanowich-Knipp, S.; Pavlovsky, A.; Bradley, P.; Saksena, A. K.; Ganguly, A.; Piwinski, J.; Girijavallabhan, V.; Njoroge, F. G. Discovery of (1R, 5 S)-N-[3-Amino-1- (cyclobutylmethyl)-2-3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)-amino] carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0] hexane-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable, hepatits C virus NS3 protease inhibitor: A potential theraputic agent for the treatment of hepatitis C infection. J. Med. Chem. 2006, 49, 6074-6086. (Pubitemid 44484951)
16. (a) Lamarre, D.; Anderson, P. C.; Bailey, M.; Beaulieu, P.; Bolger, G.; Bonneau, P.; Bös, M.; Cameron, D. R.; Cartier, M.; Cordingley, M. G.; Faucher, A.-M.; Goudreau, N.; Kawai, S. H.; Kukolj, G.; Lagacé, L.; LaPlante, S. R.; Narjes, H.; Poupart, M.-A.; Rancourt, J.; Sentjens, R. E.; George, T. S.; Simoneau, B.; Steinmann, G.; Thibeault, D.; Tsantrizos, Y. S.; Weldon, S. M.; Yong, C.-L.; Llinàs-Brunet, M. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature (London) 2003, 186-189. (Pubitemid 37442587)
17. (b) Yip, Y.; Victor, F.; Lamar, J.; Johnson, R.; Wang, Q. M.; Barket, D.; Glass, J.; Jin, L.; Liu, L.; Venable, D.; Wakulchik, M.; Xie, C.; Heinz, B.; Villarreal, E.; Colacino, J.; Yumibe, N.; Tebbe, M.; Munroe, J.; Chen, S.-H. Discovery of a novel bicycloproline P2 bearing peptidyl [alpha]-ketoamide LY514962 as HCV protease inhibitor. Bioorg. Med. Chem. Lett. 2004, 14, 251-256. (Pubitemid 38010227)
18. (c) Liverton, N. J.; Holloway, M. K.; McCauley, J. A.; Rudd, M. T.; Butcher, J. W.; Carroll, S. S; DiMuzio, J.; Fandozzi, C.; Gilbert, K. F.; Mao, S.-S.; McIntyre, C. J.; Nguyen, K. T.; Romano, J. J.; Stahlhut, M.; Wan, B.-L.; Olsen, D. B.; Vacca, J. P. Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease. J. Am. Chem. Soc. 2008, 130, 4607-4609.
19. (d) Seiwert, S. D.; Andrews, S. W.; Jiang, Y.; Serebryany, V.; Tan, H.; Kossen, K.; Rajagopalan, P. T. R.; Misialek, S.; Stevens, S. K.; Stoycheva, A.; Hong, J.; Lim, S. R.; Qin, X.; Rieger, R.; Condroski, K. R.; Zhang, H.; Do, M. G.; Lemieux, C.; Hingorani, G. P.; Hartley, D. P.; Josey, J. A.; Pan, L.; Beigelman, L.; Blatt, L. M. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob. Agents Chemother. 2008, 52 (12), 4432-4441.
20. (e) Raboisson, P.; de Kock, H.; Rosenquist, A.; Nilsson, M.; Salvador-Oden, L.; Lin, T.-I.; Roue, N.; Ivanov, V.; Wahling, H.; Wickstrom, K.; Hamelink, E.; Edlund, M.; Vrang, L.; Vendeville, S.; Van de Vreken, W.; McGowan, D.; Tahri, A.; Hu, L.; Boutton, C.; Lenz, O.; Delouvroy, F.; Pille, G.; Surleraux, D.; Wigerinck, P.; Samuelsson, B.; Simmen, K. Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350. Bioorg. Med. Chem. Lett. 2008, 18, 4853-4858.
21. (a) Zhang, R.; Beyer, B. M.; Durkin, J.; Ingram, R.; Njoroge, F. G.; Windsor, W. T.; Malcolm, B. A. A continuous spectrophotometric assay for the Hepatitis C virus serine protease. Anal. Biochem. 1999, 270, 268-275. (Pubitemid 29252538)
22. (b) Morrison, J. F.; Walsh, C. T. The Behavior and Significance of Slow Binding Enzyme Inhibitors. In Advances in Enzymology; Meister, A., Ed.; Wiley-Interscience: New York, 1988; Vol.61, pp 201-301.
23. Lohmann, V.; Körner, F.; Koch, J.-O.; Herian, U.; Theilmann, L.; Bartenschlager, R. Replication of subgenomic Hepatitis C virus RNAs in a Hepatoma cell line. Science 1999, 285, 110-113. (Pubitemid 29307577)
24. Arasappan, A.; Venkatraman, S.; Padilla, A. I.; Wu, W.; Meng, T.; Jin, Y.; Wong, J.; Prongay, A.; Girijavallabhan, V.; Njoroge, F. G. Practical and efficient method for amino acid derivatives containing β-quaternary center: Application toward synthesis of hepatitis C virus NS3 serine protease inhibitors. Tetrahedron Lett. 2007, 48, 6343-6347. (Pubitemid 47211230)